Huntington’s Disease - search results
If you're not happy with the results, please do another search
Doctors Osama Al Dalahmah and James E. Goldman discuss their work on single Nuclei RNA sequencing of Huntington’s disease brain tissues.
Dr. James E Goldman and Dr. Osama Al-Dalahmah from the Department of Pathology and Cell Biology at Columbia University, provide an in-depth perspective on Huntington’s disease (HD) research.
Cecilia Van Cauwenberghe from Frost & Sullivan’s TechCasting Group, describes the present concern and future therapeutic perspective on Huntington’s disease.
Dr Gerry Morrow shares his thoughts on the rare, progressive neurodegenerative illness, Huntington’s disease (HD).
Chief Executive of the Huntington’s Disease Association, Cath Stanley shares the latest updates on Huntington’s research from the 2018 conference.
Leora Fox, Jennifer Simpson and George Yohrling from the Huntington’s Disease Society of America explore the sources of funding in the development of therapies for Huntington’s disease (HD).
Professor Tanese of the New York University School of Medicine discusses Huntington’s disease Mutation in the huntingtin gene causes Huntington’s disease, a heritable and fatal neurodegenerative disease. The production of mutant huntingtin (HTT) protein is thought to be responsible for alterations of normal processes that ultimately result in the death of neurons....
Sorcha McPhillips, Chief Executive of the Huntington’s disease (HD) Association for Northern Ireland, raises awareness of HD and discusses the impact of hope on the community in the face of new treatments
Svein Olaf Olsen and Maiken Arnesen from the European Huntington Association reveal their thoughts on a recent and significant breakthrough concerning Huntington’s Disease (HD) research The 11th December 2017 will probably go into history along with the discovery of the Huntington gene in 1993. On this date, IONIS Pharmaceuticals announced...
Chief Executive of the Huntington’s disease Association, Cath Stanley explores the symptoms, causes, and the vital role of research within the field
New York University School of Medicine’s Naoko Tanese explores the pathogenic mechanisms and therapeutic strategies for Huntington’s disease
Jennifer Simpson of the Huntington’s disease Society of America highlights the disease and how there is still a long way to go before it can be truly understood
Dr David Moorhouse, General Neurologist, discusses the way that different diseases respond to different types of medical cannabis.
Cecilia Van Cauwenberghe from Frost & Sullivan’s TechVision Group, provides an overview of Neurodegenerative Diseases.
Prof Dr Regina Fluhrer, from the University of Augsburg, explains how intramembrane proteases have been implicated in the emergence of neurodegenerative diseases.
Naoko Tanese from New York University School of Medicine outlines their work around Huntington’s disease (HD) and new targets for therapeutic intervention
Background of Alzheimer’s disease Alzheimer’s disease (AD) is one of the most devastating neurodegenerative disorders affecting more than 25 million people worldwide which is the fifth leading cause of death for those aged 65 years and above. The disease typically starts with a difficulty to remember new information and as...
Welcome to the packed July 2018 edition of North America Analysis. One of the many insights in this edition comes from the Huntington’s Disease Society of America who explores the sources of funding in the development of therapies for Huntington’s disease (HD) in the U.S. today
Ruth Smith, COO at Christchurch Group, applauds England's 27 Major Trauma Centres provision of rehabilitation prescriptions for Acquired Brain Injury care.
Astri Arnesen, President of the European Huntington Association argues that building a partnership with patients is the best way forward to promote better and sustainable health services
12Page 1 of 2